Developing novel targeted and immune therapy approaches for acute myeloid leukemia (AML). The goal of the research in Dr. Eckfeldt's lab is to investigate the genetics and signaling pathways that drive acute myeloid leukemia (AML) to provide a foundation for the development of novel targeted and immune treatment approaches for AML. His research is focused on identifying the critical pathways that drive AML growth and survival, evaluating the effects of targeted therapies in preclinical cancer models, and studying how targeted therapies influence the susceptibility of cancer cells to immune therapies such as Natural Killer (NK) cell immunotherapy, an area of institutional expertise.

Get the latest thought leadership on AML delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.

Thanks to our HealthTree Community for AML Sponsors:

Bristol Myers Squibb
Jazz Pharmaceuticals
AbbVie
Genentech
Amgen

Follow Us

facebook instagram twitter youtube

 

Terms of Use and Privacy Policy     Newsroom     About    Donations    Find an AML Specialist     Newsletter     Learn     Connect

 

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

https://www.guidestar.org/profile/45-5354811